(Q89001788)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29872140%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

title

Antibodies and tuberculosis: finally coming of age? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29872140%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29872140%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

Babak Javid

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29872140%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

publication date

1 September 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29872140%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Immunology

30 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29872140%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

volume

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29872140%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29872140%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

page(s)

591-596

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29872140%20AND%20SRC:MED&resulttype=core&format=json

Progress in tuberculosis vaccine development and host-directed therapies--a state of the art review.

30 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0028-0

7 January 2021

Association of Human Antibodies to Arabinomannan With Enhanced Mycobacterial Opsonophagocytosis and Intracellular Growth Reduction

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0028-0

7 January 2021

Latently and uninfected healthcare workers exposed to TB make protective antibodies against Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0028-0

7 January 2021

A Functional Role for Antibodies in Tuberculosis

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0028-0

7 January 2021

Human isotype-dependent inhibitory antibody responses against Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0028-0

7 January 2021

Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0028-0

7 January 2021

Return to the Past: The Case for Antibody-Based Therapies in Infectious Diseases

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0028-0

7 January 2021

Mouse model of tuberculosis

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0028-0

7 January 2021

Tuberculosis in patients with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0028-0

7 January 2021

B cells moderate inflammatory progression and enhance bacterial containment upon pulmonary challenge with Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0028-0

7 January 2021

Increase of tuberculous infection in the organs of B cell-deficient mice

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0028-0

7 January 2021

Activated B cells in the granulomas of nonhuman primates infected with Mycobacterium tuberculosis.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0028-0

7 January 2021

Effects of B Cell Depletion on Early Mycobacterium tuberculosis Infection in Cynomolgus Macaques.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0028-0

7 January 2021

Antibody-mediated immunity against tuberculosis: implications for vaccine development

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0028-0

7 January 2021

A novel human IgA monoclonal antibody protects against tuberculosis

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0028-0

7 January 2021

Prevention of the post-chemotherapy relapse of tuberculous infection by combined immunotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0028-0

7 January 2021

A mycobacterial lipoarabinomannan specific monoclonal antibody and its F(ab') fragment prolong survival of mice infected with Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0028-0

7 January 2021

The heparin-binding haemagglutinin of M. tuberculosis is required for extrapulmonary dissemination.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0028-0

7 January 2021

A mAb recognizing a surface antigen of Mycobacterium tuberculosis enhances host survival

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0028-0

7 January 2021

Passive serum therapy with polyclonal antibodies against Mycobacterium tuberculosis protects against post-chemotherapy relapse of tuberculosis infection in SCID mice

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0028-0

7 January 2021

Therapeutic efficacy of high-dose intravenous immunoglobulin in Mycobacterium tuberculosis infection in mice

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0028-0

7 January 2021

Enhancement activity of anti-mycobacterial sera in experimental Mycobacterium bovis (BCG) infection in mice

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0028-0

7 January 2021

Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0028-0

7 January 2021

Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0028-0

7 January 2021

Selective presentation of MVA85A tuberculosis booster vaccine preclinical animal data

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0028-0

7 January 2021

CD4 T Cell-Derived IFN-γ Plays a Minimal Role in Control of Pulmonary Mycobacterium tuberculosis Infection and Must Be Actively Repressed by PD-1 to Prevent Lethal Disease

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0028-0

7 January 2021

Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0028-0

7 January 2021

Does antibody to mycobacterial antigens, including lipoarabinomannan, limit dissemination in childhood tuberculosis?

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0028-0

7 January 2021

Risk of tuberculosis among healthcare workers in an intermediate-burden country: a nationwide population study.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0028-0

7 January 2021

Latent tuberculosis infection and occupational protection among health care workers in two types of public hospitals in China

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0028-0

7 January 2021

https://api.crossref.org/works/10.1038%2FS41577-018-0028-0

1 reference

7 January 2021

The Type of Growth Medium Affects the Presence of a Mycobacterial Capsule and Is Associated With Differences in Protective Efficacy of BCG Vaccination Against Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0028-0

7 January 2021

Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0028-0

7 January 2021

Direct visualization by cryo-EM of the mycobacterial capsular layer: a labile structure containing ESX-1-secreted proteins

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0028-0

7 January 2021

Mycobacterium tuberculosis proteome microarray for global studies of protein function and immunogenicity

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0028-0

7 January 2021

Enhanced control of Mycobacterium tuberculosis extrapulmonary dissemination in mice by an arabinomannan-protein conjugate vaccine.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0028-0

7 January 2021

A baculovirus-conjugated mimotope vaccine targeting Mycobacterium tuberculosis lipoarabinomannan

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0028-0

7 January 2021

Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0028-0

7 January 2021

The protective effect of immunoglobulin in murine tuberculosis is dependent on IgG glycosylation.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0028-0

7 January 2021

Multiplex opsonophagocytosis assay (MOPA): a useful tool for the monitoring of the 7-valent pneumococcal conjugate vaccine

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0028-0

7 January 2021

Phagosome-lysosome interactions in cultured macrophages infected with virulent tubercle bacilli. Reversal of the usual nonfusion pattern and observations on bacterial survival

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0028-0

7 January 2021

Naturally produced opsonizing antibodies restrict the survival of Mycobacterium tuberculosis in human macrophages by augmenting phagosome maturation

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0028-0

7 January 2021

Live oral Salmonella enterica serovar Typhi vaccines Ty21a and CVD 909 induce opsonophagocytic functional antibodies in humans that cross-react with S. Paratyphi A and S. Paratyphi B

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0028-0

7 January 2021

Antibody is required for protection against virulent but not attenuated Salmonella enterica serovar typhimurium

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0028-0

7 January 2021

Fast vaccine design and development based on correlates of protection (COPs).

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0028-0

7 January 2021

Immune correlates of vaccine protection against HIV-1 acquisition

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0028-0

7 January 2021

Tuberculosis vaccines: barriers and prospects on the quest for a transformative tool

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0028-0

7 January 2021

The essential mycobacterial amidotransferase GatCAB is a modulator of specific translational fidelity.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0028-0

7 January 2021

Aerial dissemination of pulmonary tuberculosis. A two-year study of contagion in a tuberculosis ward. 1959.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0028-0

7 January 2021

Ultra-low dose of Mycobacterium tuberculosis aerosol creates partial infection in mice

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0028-0

7 January 2021

A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0028-0

7 January 2021

A humanized mouse model of tuberculosis

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0028-0

7 January 2021

Humanized NOG mice as a model for tuberculosis vaccine-induced immunity: a comparative analysis with the mouse and guinea pig models of tuberculosis.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0028-0

7 January 2021

BCG - old workhorse, new skills.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0028-0

7 January 2021

Rhesus macaques are more susceptible to progressive tuberculosis than cynomolgus macaques: A quantitative comparison

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0028-0

7 January 2021

Experimental human challenge infections can accelerate clinical malaria vaccine development

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0028-0

7 January 2021

First human challenge testing of a pneumococcal vaccine. Double-blind randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0028-0

7 January 2021

Evaluation of the Clinical and Microbiological Response to Salmonella Paratyphi A Infection in the First Paratyphoid Human Challenge Model

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0028-0

7 January 2021

The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0028-0

7 January 2021

Development of RTS,S/AS02: a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0028-0

7 January 2021

Systems serology for evaluation of HIV vaccine trials

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0028-0

7 January 2021

Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0028-0

7 January 2021

The Recombinant Bacille Calmette-Guérin Vaccine VPM1002: Ready for Clinical Efficacy Testing

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0028-0

7 January 2021

Antibody therapies for the prevention and treatment of viral infections.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0028-0

7 January 2021

10.1038/S41577-018-0028-0

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29872140%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

1 reference